-
Mashup Score: 4Suneel Kamath: Standing Strong: ASCO Honors Advocacy Commitment in Oncology - OncoDaily - 9 day(s) ago
Suneel Kamath: Standing Strong: ASCO Honors Advocacy Commitment in Oncology / Advocacy Champion, affecting issues, ASCO, cancer, cancer community, Cancer
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10White House Minority Health Forum - 13 day(s) ago
The White House
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Colorectal Cancer Liver Metastasis - 1 month(s) ago
Tune in to learn about the current state of disease management and the potential of ctDNA testing to guide treatment decisions and monitor disease progression.
Source: my.clevelandclinic.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Colorectal Cancer Liver Metastasis - 2 month(s) ago
Tune in to learn about the current state of disease management and the potential of ctDNA testing to guide treatment decisions and monitor disease progression.
Source: my.clevelandclinic.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer - 2 month(s) ago
Scientific Reports – Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Stomach cancer killed Toby Keith at 62. The disease can strike young and be hard to spot. - 3 month(s) ago
Stomach cancer used to be a leading killer in the United States, and continues to have easy-to-mistake symptoms. Here’s when to talk to a doctor.
Source: www.usatoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44
PURPOSE National Cancer Institute (NCI) and nonprofit organization (NPO) funding is critical for research and advocacy but may not be equitable across cancers. METHODS This study evaluated funding from the NCI and NPOs supporting lung, breast, colorectal, pancreatic, hepatobiliary, prostate, ovarian, cervical and endometrial cancers, leukemia, lymphoma, and melanoma from 2015 to 2018. The primary objectives were to assess for funding disparities across different cancers compared with their incidence and mortality and across racial groups. We also determined if underfunding correlates with fewer clinical trials. Correlations between funding for each cancer and its incidence, mortality, and number of clinical trials were analyzed using descriptive statistics and Pearson correlation coefficients (CCs). RESULTS Diseases with the largest combined NCI and NPO funding were breast cancer ($3.75 billion in US dollars [USD]) and leukemia ($1.99 billion USD). Those with the least funding were end
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12
PURPOSE National Cancer Institute (NCI) and nonprofit organization (NPO) funding is critical for research and advocacy but may not be equitable across cancers. METHODS This study evaluated funding from the NCI and NPOs supporting lung, breast, colorectal, pancreatic, hepatobiliary, prostate, ovarian, cervical and endometrial cancers, leukemia, lymphoma, and melanoma from 2015 to 2018. The primary objectives were to assess for funding disparities across different cancers compared with their incidence and mortality and across racial groups. We also determined if underfunding correlates with fewer clinical trials. Correlations between funding for each cancer and its incidence, mortality, and number of clinical trials were analyzed using descriptive statistics and Pearson correlation coefficients (CCs). RESULTS Diseases with the largest combined NCI and NPO funding were breast cancer ($3.75 billion in US dollars [USD]) and leukemia ($1.99 billion USD). Those with the least funding were end
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis - 5 month(s) ago
Outcome of DPYD variant allele carriers treated with dose-individualized fluoropyrimidine therapy.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Metabolomic Differences: Young Onset (yoCRC) vs. Average Onset (aoCRC) Colorectal Cancer - 7 month(s) ago
Listen as Dr. Kamath talks about the challenges associated with early detection, the evolving landscape of screening guidelines, potential contributing factors to the rise of yoCRC, and the role of metabolomics in unraveling the complexities of colorectal cancer.
Source: my.clevelandclinic.orgCategories: Latest Headlines, Oncologists1Tweet
RT @oncodaily: Standing Strong: @ASCO Honors Advocacy Commitment in Oncology - @SKamath_MD https://t.co/qos68SHE3s #oncodaily #oncology #…